A20 (TNFAIP3) Alleviates CVB3-Induced Myocarditis via Inhibiting NF-κB Signaling

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Gui, Jun ^a   Yue, Yan ^b   Chen, Ruizhen ^a   Xu, Wei ^b   Xiong, Sidong ^a,b  

^a FUDAN UNIVERSITY   (China)

^b SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; CREATINE KINASE; CREATINE KINASE MB; CYTOPLASM PROTEIN; I KAPPA B ALPHA; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSCRIPTION FACTOR RELA; TROPONIN I; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INDUCED PROTEIN 3; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL VIABILITY; CONSENSUS SEQUENCE; CONTROLLED STUDY; COXSACKIE VIRUS B; CREATINE KINASE BLOOD LEVEL; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE OVEREXPRESSION; HEART MUSCLE CELL; HEART PROTECTION; HISTOPATHOLOGY; MALE; MOUSE; NEWBORN; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REMISSION; SIGNAL TRANSDUCTION; SURVIVAL RATE; UBIQUITINATION; UPREGULATION; VIRUS MYOCARDITIS; WEIGHT REDUCTION;

ADENOVIRIDAE; ANIMALS; CELLS, CULTURED; COXSACKIEVIRUS INFECTIONS; CYSTEINE ENDOPEPTIDASES; CYTOKINES; ENTEROVIRUS B, HUMAN; GENETIC VECTORS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, INBRED BALB C; MYOCARDITIS; MYOCARDIUM; MYOCYTES, CARDIAC; NF-KAPPA B; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECOMBINANT PROTEINS; TNF RECEPTOR-ASSOCIATED FACTOR 6; UBIQUITINATION;

ADENOVIRIDAE; COXSACKIEVIRUS; MUS;

EID: 84867025596     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046515     Document Type: Article

References (49)

1. Esfandiarei M, McManus BM, (2008) Molecular biology and pathogenesis of viral myocarditis. Annu Rev Pathol 3: 127-155.
2. Feldman AM, McNamara D, (2000) Myocarditis. N Engl J Med 343: 1388-1398.
3. Fairweather D, Rose NR, (2007) Coxsackievirus-induced myocarditis in mice: a model of autoimmune disease for studying immunotoxicity. Methods 41: 118-122.
4. Klingel K, Kandolf R (1993) The role of enterovirus replication in the development of acute and chronic heart muscle disease in different immunocompetent mouse strains. Scand J Infect Dis Suppl 88: 79-85.
5. Badorff C, Fichtlscherer B, Rhoads RE, Zeiher AM, Muelsch A, et al. (2000) Nitric oxide inhibits dystrophin proteolysis by coxsackieviral protease 2A through S-nitrosylation: a protective mechanism against enteroviral cardiomyopathy. Circulation 102: 2276-2281.
6. Fuse K, Chan G, Liu Y, Gudgeon P, Husain M, et al. (2005) Myeloid differentiation factor-88 plays a crucial role in the pathogenesis of Coxsackievirus B3-induced myocarditis and influences type I interferon production. Circulation 112: 2276-2285.
7. Pankuweit S, Ruppert V, Maisch B, (2004) Inflammation in Dilated Cardiomyopathy. Herz 29: 788-793.
8. Leipner C, Grun K, Borchers M, Stelzner A, (2000) The outcome of coxsackievirus B3-(CVB3-) induced myocarditis is influenced by the cellular immune status. Herz 25: 245-248.
9. Calabrese F, Thiene G, (2003) Myocarditis and inflammatory cardiomyopathy: microbiological and molecular biological aspects. Cardiovasc Res 60: 11-25.
10. Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S, (1994) Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J 72: 561-566.
11. Levine B, Kalman J, Mayer L, Fillit HM, Packer AM, (1990) Elevated circulating levels of tumor necrosis factor in sever chronic heart failure. N Engl J Med 323: 236-241.
12. Schultz JC, Hilliard AA, Cooper LT, Rihal CS, (2009) Diagnosis and treatment of viral myocarditis. Mayo Clin Proc 84: 1001-1009.
13. Yamada T, Matsumori A, Sasayama S, (1994) Therapeutic effect of anti-tumor necrosis factor-alpha antibody on the murine model of viral myocarditis induced by encephalomyocarditis virus. Circulation 89: 846-851.
14. Shen Y, Xu W, Chu YW, Wang Y, Liu QS, et al. (2004) Coxsackievirus group B type 3 infection upregulates expression of monocyte chemoattractant protein 1 in cardiac myocytes, which leads to enhanced migration of mononuclear cells in viral myocarditis. J Virol 78: 12548-12556.
15. Fan Y, Weifeng W, Yuluan Y, Qing K, Yu P, et al. (2011) Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of coxsackievirus b3-induced viral myocarditis reduces myocardium inflammation. Virol J 8: 2-7.
16. Yue Y, Gui J, Xu W, Xiong SD, (2011) Gene therapy with CCL2 (MCP-1) mutant protects CVB3-induced myocarditis by compromising Th1 polarization. Mol Immunol 48: 706-713.
17. Yue Y, Gui J, Ai WQ, Xu W, Xiong SD, (2011) Direct Gene transfer with IP-10 mutant ameliorates mouse CVB3-Induced myocarditis by blunting Th1 immune responses. PLoS One 6: 1-8.
18. Lv K, Xu W, Wang CN, Niki T, Hirashima M, et al. (2011) Galectin-9 administration ameliorates CVB3 induced myocarditis by promoting the proliferation of regulatory T cells and alternatively activated Th2 cells. Clin Immunol 140: 92-101.
19. Huber SA, Feldman AM, Sartini D, (2006) Coxsackievirus B3 induces T regulatory cells which inhibit cardiomyopathy in TNF transgenic mice. Cir Res 99: 1109-1116.
20. Li K, Xu W, Guo Q, Jiang ZG, Wang P, et al. (2009) Differential macrophage polarization in male and female BALB/c mice infected with coxsackievirus B3 defines susceptibility to viral myocarditis. Circ Res 105: 353-364.
21. Vereecke L, Beyaert R, Loo GV, (2009) The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol 30: 383-391.
22. Coornaert B, Carpentier I, Beyaert R, (2009) A20: central gatekeeper in inflammation and immunity. J Biol Chem 284: 8217-8221.
23. Lee EG, Boone DL, Chai S, Libby SL, Chen M, et al. (2000) Failure to regulate TNF-induced NF-κB and cell death responses in A20-deficient mice. Science 289: 2350-2354.
24. Kang NI, Yoon HY, Lee YR, Won M, Chung MJ, et al. (2009) A20 attenuates allergic airway inflammation in mice. J Immunol 183: 1488-1495.
25. Hah YS, Lee YR, Jun JS, Lim HS, Kim HO, et al. (2010) A20 suppresses inflammatory responses and bone destruction in human fibroblast-like synoviocytes and in mice with collagen-induced arthritis. Arthritis Rheum 62: 2313-2321.
26. Wolfrum S, Teupser D, Tan M, Chen KY, Breslow JL, (2007) The protective effect of A20 on atherosclerosis in apolipoprotein E-deficient mice is associated with reduced expression of NF-κB target genes. Proc Natl Acad Sci USA 104: 18601-18606.
27. Grabie N, Delfs MW, Westrich JR, Love VA, Stavrakis G, et al. (2003) IL-12 is required for differentiation of pathogenic CD8+ T cell effectors that cause myocarditis. J Clin Invest 111: 671-680.
28. Gay RT, Belisle S, Beck MA, Meydani SN, (2006) An aged host promotes the evolution of avirulent coxsackievirus into a virulent strain. Proc Natl Acad Sci USA 103: 13825-13830.
29. Song XT, Evel-Kabler K, Shen L, Rollins L, Huang XF, et al. (2008) A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression. Nat Med 14: 258-265.
30. Bonci D, Cittadini A, Latronico MV, Borello U, Aycock JK, et al. (2003) 'Advanced' generation lentiviruses as efficient vectors for cardiomyocyte gene transduction in vitro and in vivo. Gene Ther 10: 630-636.
31. Li HL, Zhou ML, Wang D, Wang AB, Cai H, et al. (2007) Targeted cardiac overexpression of A20 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circulation 115: 1885-1894.
32. Kuper R, Scheinman RI, (2002) Measurement of IKK activity in primary rat T cells: rapid activation and inactivation. J Immunol Methods 266: 155-164.
33. Lawrence T, (2009) The nuclear factor NF-κB pathway in inflammation. Cold Spring Harb Perspect Biol 1: 1-13.
34. Yajima T, (2011) Viral myocarditis: potential defense mechanisms within the cardiomyocytes against virus infection. Future Microbiol 6: 551-566.
35. Wertz IE, O'Rourke KM, Zhou H, Eby M, Aravind L, et al. (2004) De-ubiquitination and ubiquitin ligase domain of A20 downregulate NF-kappaB signaling. Nature 430: 694-699.
36. Boone DL, Turer EE, Lee EG, Ahmad RC, Wheeler MT, et al. (2004) The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol 5: 1052-1060.
37. Hitotsumatsu O, Ahmad RC, Tavares R, Wang M, Philpott D, et al. (2008) The Ubiquitin-editing enzyme A20 restricts nucleotide-binding oligomerization domain containing 2-triggered signals. Immunity 28: 381-390.
38. Corsten MF, Schroen B, Heymans S, (2012) Inflammation in viral myocarditis: friend or foe. Trends Mol Med 18: 426-437.
39. Thomson W, Barton A, Ke X, Eyre S, Hinks A, et al. (2007) Rheumatoid arthritis association at 6q23. Nat Genet 39: 1431-1433.
40. Trynka G, Zhernakova A, Romanos J, Franke L, Hunt KA, et al. (2007) Coeliac disease associated risk variants in TNFAIP3 and REL implicate altered NF-κB signalling. Gut 58: 1078-1083.
41. Graham RR, Cotsapas C, Davies L, Hackett R, Lessard CJ, et al. (2008) Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nat Genet 40: 1059-1061.
42. Grey ST, Arvelo MB, Hasenkamp W, Bach FH, Ferran C, (1999) A20 inhibits cytokine induced apoptosis and nuclear factor κB-dependent gene activation in islets. J Exp Med 190: 1135-1146.
43. Maelfait J, Roose K, Bogaert P, Sze M, Saelens X, et al. (2012) A20 (Tnfaip3) deficiency in myeloid cells protects against influenza A virus infection. PLoS Pathog 8: 1-11.
44. Matsumori A, Nunokawa Y, Yamaki A, Yamamoto K, Hwang MW, et al. (2004) Suppression of cytokines and nitric oxide production, and protection against lethal endotoxemia and viral myocarditis by a new NF-kappaB inhibitor. Eur J Heart Fail 6: 137-144.
45. Garmaroudi FS, Marchant D, Si XN, Khalili A, Bashashati A, et al. (2010) Pairwise network mechanisms in the host signaling response to coxsackievirus B3 infection. Proc Natl Acad Sci USA 107: 17053-17058.
46. Esfandiarei M, Boroomand S, Suarez A, Si XN, Rahmani M, et al. (2007) Coxsackievirus B3 activates nuclear factor kappa B transcription factor via a phosphatidylinositol-3 kinase/protein kinase B-dependent pathway to improve host cell viability. Cell Microbiol 9: 2358-2371.
47. Parvatiyar K, Harhaj EW, (2011) Regulation of inflammatory and antiviral signaling by A20. Microbes Infect 13: 209-215.
48. Onose A, Hashimoto S, Hayashi S, Maruoka S, Kumasawa F, et al. (2006) An inhibitory effect of A20 on NF-kappaB activation in airway epithelium upon influenza virus infection. Eur J Pharmacol 541: 198-204.
49. Cook SA, Novikov MS, Ahn Y, Matsui T, Rosenzweig A, (2003) A20 is dynamically regulated in the heart and inhibits the hypertrophic response. Circulation 108: 664-667.